The use of nanotechnology in cardiovascular disease by Chandarana, M et al.
Vol.:(0123456789) 
Applied Nanoscience 
https://doi.org/10.1007/s13204-018-0856-z
REVIEW ARTICLE
The use of nanotechnology in cardiovascular disease
Meera Chandarana1 · Anthony Curtis1 · Clare Hoskins1 
Received: 3 May 2018 / Accepted: 10 August 2018 
© The Author(s) 2018
Abstract
Cardiovascular diseases claim a number of lives globally; many of which are preventable. With the increase in diets that 
consist of high saturated fat, salt, and sugar, people often living sedentary lifestyles, and a rise in cases of obesity, the inci-
dence of cardiovascular disease is increasing. These contributing factors, coupled with more advanced methods of diagnosis, 
have delivered statistics that clearly show that there is a rising trend in the prevalence of cardiovascular disease. Treatment 
for cardiovascular diseases is limited currently to oral medicines or invasive surgery. There is a huge gap in this area of 
medicine for novel therapeutics for improved patient outcomes. Nanotechnology may provide a solution to more effective 
treatment of disease, with better prognoses and a reduced side effect profile. This review will explore for potential solutions 
to the limited pharmacological therapies currently on the market and the future that lies ahead for the place of nanotechnol-
ogy within cardiovascular medicine.
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Introduction
Cardiovascular diseases (CVDs) are the leading cause of 
death worldwide, claiming 17.7 million lives in 2015, and 
this figure is projected to increase to 23.6 million in 2030 
(WHO 2017). The term ‘cardiovascular diseases’ encom-
passes, but is not limited to coronary heart disease, deep vein 
thrombosis, pulmonary embolism, and myocardial infarction 
(MI), all of which result in ischaemia and tissue death. Of 
these, MI and heart failure are the major conditions which 
lead to mortality.
A MI, known commonly as a heart attack, is the result 
of total occlusion of the major arteries supplying the heart 
leading to a decrease in blood flow, oxygen, and nutrient 
supply. Ultimately, this results in myocardial tissue death by 
apoptosis or necrosis due to coronary occlusion. An MI can 
manifest as two different forms, ST-elevation MI (STEMI) 
or non-ST-elevation MI (NSTEMI), dependant on the vis-
ible changes on an ECG trace (NICE 2013). The current 
treatment for MI is reperfusion in the shortest period of 
time following arterial obstruction, which can be achieved 
through invasive methods such as percutaneous coronary 
intervention (PCI) or coronary artery bypass graft (CABG), 
or through pharmacological therapy (Ruiz-Esparza et al. 
2013).
Heart failure is a clinical disease state that presents with 
symptoms of breathlessness, peripheral oedema, and fatigue, 
all of which are a result of reduced cardiac functionality 
(Ponikowski et al. 2016). This form of cardiomyopathy is a 
state in which the heart muscle is unable to pump efficiently 
to satisfy the body’s metabolic requirements (Ruiz-Esparza 
et al. 2013). Disease of the coronary artery is the largest 
contributory factor in the development of heart failure (Fox 
et al. 2001). Heart failure is an umbrella term that refers to 
a range of various cardiac syndromes, including: left-ven-
tricular dysfunction, valvular, pericardial, or endocardial 
abnormalities, and irregularity of rhythm (Ponikowski et al. 
2016). It is estimated that up to 2 million people are living 
with heart failure in the UK, a figure that is continuously 
increasing due primarily to the significantly aging popula-
tion (Mitchell et al. 2015). Currently, guidance recommends 
ACE inhibitors and β-receptor blockers as the first-line treat-
ment for heart failure (NICE 2010).
The current statistics regarding the incidence of CVDs 
highlight the need for new therapies and technological 
advancements to combat these diseases.
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Atherosclerosis is the precursor to several vascular dis-
eases. Atherosclerotic plaques are formed of macrophage 
cells, fat, cholesterol, and calcium, which become deposited 
in the vasculature and the growing plaques harden over time. 
This results in narrowing of the blood vessels, a reduction 
in blood flow, rupture, and ultimately ischaemia ((Weaver 
2013) (Fig. 1). Histologically, the rupture of plaques, which 
leads to a cardiovascular event, is a result of poor fibrous 
plaque caps containing increased concentrations of matrix 
metalloproteinases (MMPs) that cause weakness in the 
plaque (Qin et al. 2016). Lifestyle factors are eminent con-
tributors to the development of atheromatous plaques. It is 
widely accepted that consuming foods rich in salt, sugar, 
and saturated fat greatly increases the risk of suffering from 
a CVD in later life. Having a high low-density lipoprotein 
(LDL)-to-high-density lipoprotein (HDL) ratio is also a risk 
factor as LDLs are deposited on the walls of blood vessels 
and contribute to the development of plaques. Hypertension, 
smoking, lack of physical activity, family history, obesity, 
age, and stress all play a role in the development of CVDs, 
estimated to cost the economy £19 billion per annum, with 
the National Health Service (NHS) bearing a burden of 
£9 billion (British Heart Foundation 2017).
Current treatments for CVDs are focussed on restoring 
normal blood flow through or around the damaged vascula-
ture and the prevention of recurrent cardiovascular insults. 
Reduction in further build up and thickening of atheroscle-
rotic plaques, as well as effects on external elastic mem-
branes and fibrous and dense calcium volumes is achieved 
by statin therapy (Banach et al. 2015). Dual antiplatelet 
therapies using cyclooxygenase inhibitors such as aspirin 
and P2Y12 inhibitor such as clopidogrel are first-line treat-
ments for prevention of CVDs, which aim to reduce clot 
formation and platelet aggregation (Kapil et al. 2017). There 
is a requirement for improvement in these treatments, pri-
marily due to the risks associated with taking antiplatelet 
therapy which significantly adverse side effect profiles, and 
poor patient compliance (Harrington et al. 2003). In addi-
tion to this, some patients do not respond well to antiplate-
let therapy, which has a negative effect on their long-term 
prognosis. Studies have demonstrated that patients who 
have suffered an acute myocardial infarction but have a low 
response to clopidogrel are at increased risk of recurrent 
cardiovascular events at follow-up (Geisler et al. 2006). This 
supports the necessity for advancements in technology and 
an opportunity for nanomedicine (Fig. 2).
Nanotechnologies for treatment
The field of nanomedicine comprises the diagnosis, 
treatment, and prevention of disease or injury to improve 
and maintain a good quality of life and health, with use 
of nanotechnology (Patil et  al. 2008). For example, a 
domain of nanomedicine aims to control and manipulate 
biomacromolecular and supramolecular entities which 
Fig. 1  Progression of atherosclerotic plaque showing narrowing of 
the blood vessel
Fig. 2  Use of nanotechnology for cardiovascular disease
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are vital to human health, encompassing DNA, RNA, 
cell membranes, and lipid bilayers (Tomalia et al. 2007). 
Nanoparticles, in particular, are widely accepted as hav-
ing physicochemical properties that improve biologi-
cal function, such as a high surface energy due to their 
large surface area to volume ratio, wettability, reactivity, 
and roughness (Jiang et al. 2017). The British Standards 
Institute defines nanoparticles as microscopic particles 
with all three dimensions in the nanoscale, ranging from 
1 to 100 nm (British Standards Institute 2011). Advance-
ments in nanomedicine research have led to better ways to 
reduce toxicity, prolong the half-life of drugs, and reduce 
side effects through alteration of nanoparticle properties, 
whilst maintaining the particle biocompatibility (Gupta 
and Gupta 2005). Targeted drug delivery in treatment of 
disease using nanoparticles is possible through active or 
passive means: active targeting requires conjugation of 
the therapeutic agent to a tissue- or cell-specific ligand, 
whereas passive targeting involves coupling of the ther-
apeutic agent to a high-molecular-weight polymer that 
has enhanced permeation and retention to vascular tissue 
(Patel and Bailey 2007).
A diverse range of nanotechnologies have been devel-
oped for biomedicine within the past 2 decades, each 
with their own unique properties and advantages. These 
include micelles, liposomes, dendrimers, nanoparticles, 
and the use of nano-coatings (De Jong and Borm 2008) 
(Fig.  3). Currently, therapeutic applications of nano-
technology within medicine are focused around cancer 
treatment and diagnosis (Sanna et al. 2014); however, 
the focus is shifting to other areas of therapeutics, such 
as cardiovascular medicine (Binsalamah et al. 2012) and 
antimicrobial resistance (Kumar et  al. 2018). Table 1 
summarises the main classes of technologies under explo-
ration in this area.
Liposomes
Liposomes form phospholipid bilayer structures, around 
50–200 nm in size, with aqueous cores encapsulated within 
natural phospholipids, such as cholesterol (Akbarzadeh 
et al. 2013). As they possess qualities of both hydrophilic-
ity and hydrophobicity, liposomes can be used as effective 
drug delivery systems. There are three classifications of 
liposomes, based on their size and number of bilayers. Vari-
able size, method of preparation, surface charge, and lipid 
composition are all contributing factors to the properties dis-
played by a liposome (Sahoo and Labhasetwar 2003). Small 
unilamellar vesicles (SUV) have a single lipid bilayer; large 
unilamellar vesicles (LUV) are similar to SUVs, whereas 
multilamellar vesicles (MLV) have numerous bilayers 
(Sahoo and Labhasetwar 2003). Manipulation of the sur-
face of liposomes can be undertaken via the addition of 
poly(ethylene glycol) (PEG), giving the carrier ‘stealth’-like 
properties (Immordino et al. 2006). The ‘stealth liposomes’ 
have a prolonged circulation time, reduced uptake, and 
reduced clearance by phagocytes or the liver (Sahoo and 
Labhasetwar 2003). Furthermore, antibodies or other tar-
geting moieties can be attached to the liposomal surface 
to target specific areas (Levchenko et al. 2012). Due to the 
processes of platelet aggregation in myocardial infarction, 
atherosclerosis, and thrombosis, platelet-targeted liposomal 
drug delivery may prove to have potential therapeutic appli-
cations (Ruiz-Esparza et al. 2013). In regard to applications 
in cardiovascular medicine, liposomes have the potential to 
be utilised to treat peripheral artery disease and intermitted 
claudication. Currently, research into the liposomal drug 
delivery of prostaglandin E-1 (PGE-1), under the trade name 
Liprostin, is undergoing phase III clinical trials (Bulbake 
et al. 2017). PGE-1 possesses a wide range of pharmacologi-
cal properties, including vasodilation, inhibition of platelet 
aggregation and leukocyte adhesion, and anti-inflammatory 
Fig. 3  Nanocarriers for the delivery of therapeutic agents: a micelle, b liposome, and c dendrimer
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qualities (Gao et al. 2010). Encapsulation of PGE-1 within 
lipid nanoparticles reduced the degradation of PGE-1 and 
improved both the prolongation of the drug outcome and the 
anti-inflammatory effect (Gao et al. 2010), exhibiting real 
potential for PGE-1-loaded lipid nanoparticles in clinical 
application.
Liposomes have been designed for targeted treatment of 
thrombosis. Thrombosis, a blockage of the blood vessels, is 
associated with myocardial infarction (and stroke). Recently, 
liposomes carrying thrombolytic drug urokinase were 
reported; these were surface functionalised with a cyclic 
arginyl-glycyl-aspartic acid (cRGD) peptide (Zhang et al. 
2018). cRGD peptides selectively bind onto the GPIIb/IIIa 
receptors on the active platelets conferring targeted delivery. 
In the cRGD, liposomes demonstrated similar effect to the 
free drug at 75% less drug dosage in a mouse mesenteric 
thrombosis model (Zhang et al. 2018).
Multiple studies have reported the encapsulation and 
delivery of berberine (Allijn et al. 2017; Lou et al. 2013; 
Sailor 2015). Berberine is a small fluorescent isoquino-
line quaternary alkaloid which has proven to be useful at 
high doses as a cardio-protectant (Zhang et al. 2014) and 
for improvement of cardiac function (Huang et al. 2015). 
Berberine-loaded liposomes have been developed and tested 
for IL-6 secretion inhibition and cardiac function protec-
tion against adverse remodelling after MI in C57BL/6J mice 
(Allijn et al. 2017). In vivo, the liposomal berberine formula-
tion significantly preserved cardiac ejection fraction 28 days 
post-MI by 64% compared with the unloaded liposomes and 
free drug. This study highlights the potential which liposo-
mal berberine formulation possess as a potential treatment 
of adverse remodelling after MI.
The use of liposomes is relatively old compared to the 
polymer-based systems and it is likely that these systems 
will be clinically applicable at an earlier stage. However, 
as observed in other liposomal drug delivery applications, 
there are some disadvantages. These include the lack of 
long-term stability of these systems resulting in premature 
drug release, as well. In addition, increased excipient-to-
drug ratios are often required making them more expensive 
and less effective than some of the polymer-based systems.
Polymeric nanoparticles
Polymeric nanoparticles have attracted particular interest 
in the nanomedicine field, due to the manipulative quali-
ties of the materials and the potential of reabsorption in the 
body (Jiang et al. 2017). The route of delivery of polymeric 
nanoparticles is dependent on their site of action and the 
most minimally invasive method of getting them into sys-
temic circulation. Intravenous injection is the most com-
mon method of administration; however, oral, mucosal, 
dermal, or transdermal administration is also viable (Elsa-
bahy and Wooley 2012). Polymeric nanoparticles make up 
a large class of systems. These include solid nanoparticles, 
amphiphilic nanoparticles (forming micelles, vesicles, and 
Table 1  Summary of nanotechnology applications in cardiovascular disease
Class Application References
Liposome Thrombosis Ruiz-Esparza et al. (2013), Zhang et al. (2018) and Palekar et al. (2013a, b)
Atherosclerosis Ruiz-Esparza et al. (2013), Chono et al. (2005), Alaarg et al. (2015) and Hosseini et al. 
(2015)
Vasodilation Bulbake et al. (2017), Jain et al. (2014) and Nahar et al. (2014)
Cardio-protectant Zhang et al. (2014), Allijn et al. (2017) and Murohara et al. (1995)
Polymeric nanoparticle Thrombosis Al Meslmani et al. (2017), Korin et al. (2012) and Pazzini et al. (2015)
Atherosclerosis Matoba et al. (2017) and Sanchez-Gaytan et al. (2015)
Cardio-protectant Giannouli et al. (2018) and Aisha et al. (2015)
Polymeric micelle Thrombosis Pan et al. (2018), Chan et al. (2016) and Pang et al. (2014)
Atherosclerosis Wu et al. (2018), Kuo et al. (2014) and Fares et al. (2018)
Vasodilation El-Gendy et al. (2017), Önyüksel et al. (1999) and Zhai et al. (2013)
Cardio-protectant Cote et al. (2015) and Siddalingappa et al. (2015)
Dendrimer Thrombosis Zhang et al. (2017), Durán-Lara et al. (2013) and Mukhametova et al. (2017)
Atherosclerosis Napoli et al. (2015)
Vasodilation Singh et al. (2017)
Cardio-protectant Wan et al. (2011)
Gelated nanoparticle Cardio-protectant Oh et al. (2010)
Nano-coating Biocompatibility of implants Tan et al. (2013), Kidane et al. (2009), Finn et al. (2005), Costa et al. (2016), CeloNova 
Biosciences (2018) and Acharya et al. (2012)
Diagnosis Imaging Kim et al. (1996), Thakor et al. (2011), Varna et al. (2018), Chen et al. (2014), Cai et al. 
(2005) and Palekar et al. (2015)
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rods), dendrimers, and star-shaped systems. All of these sys-
tems possess their own unique architecture and properties 
(Hoskins et al. 2012). In general, polymer-based systems are 
more cost-effective and easier to manufacture and scale up 
compared to liposomes with longer stability profiles.
There are a number of non-biodegradable polymers such 
as poly(methyl methacrylate) (PMMA), poly(acrylamide), 
poly(styrene), and poly(acrylates), (Banik et al. 2016); how-
ever, chronic toxicity has been observed in studies using 
these materials. This has led a focus on biodegradable poly-
mers (Burman et al. 2015), examples of which include syn-
thetic polymers such as poly(lactide) (PLA), poly(lactide-co-
glycolide) copolymers (PLGA), poly(ε-caprolactone) (PCL), 
and 17 and poly(amino acids) (Elsabahy and Wooley 2012).
Expanded polytetrafluoroethylene (ePTFE) grafts are 
most commonly used to substitute blood vessels that have 
been damaged as a result of ischaemia or atherosclerotic 
plaques, re-establishing regular blood flow. A study was 
conducted using poly(lactic-co-glycolic acid) (PLGA) nano-
particles covalently bonded to ePTFE surfaces to test their 
therapeutic effects. Following oxidation of the ePTFE sur-
face using  H2O2/H2SO4, aminolyzation using 3-aminopropyl 
triethoxysilane was undertaken. The nanoparticles showed 
good stability on the ePTFE surface and the biocompatibil-
ity of the graft with mouse fibroblasts which demonstrated 
no substantial cytotoxicity (Al Meslmani et al. 2017), sug-
gesting promise for the use of ePTFE for the treatment of 
CVD by incorporating antithrombotic drugs to the polymer 
grafts. Korin et al. (2012) studied the effects of biodegrad-
able poly(lactic-co-glycolic) acid (PLGA) nanoparticles 
laden with the enzyme tissue plasminogen activator (tPA) 
which aids in the dispersion of clots. The nanoparticles were 
designed specifically to disintegrate and release the drug 
upon encountering high shear stress resulting from the nar-
rowing of the surrounding vasculature (Korin et al. 2012). 
In in vivo studies, the complexes released tPA rapidly, thus 
dissolving the clot swiftly, which increased the survival rate 
following an induced pulmonary embolism (Korin et al. 
2012). Furthermore, the results indicated that lower doses 
of tPA were required if it was incorporated in the polymeric 
grafts, suggesting a reduced side effect profile. This research 
clearly indicates that there are applications for this technol-
ogy in the treatment of CVDs with the potential to transform 
cardiovascular medicine.
Quercetin (Qu) encapsulated within polymeric nanopar-
ticles (Giannouli et al. 2018) or as solid drug nanoparti-
cles (Kakran et al. 2012; Tefas et al. 2015) has been the 
subject of a number of investigations. Qu is an antioxidant 
drug which has shown to protect against CVDs. One recent 
study reported a novel poly(lactic-co-glycolic acid) (PLGA) 
loaded with Qu for atherosclerosis prevention (Giannouli 
et al. 2018). The particles showed promising encapsula-
tion efficiencies and drug release profiles indicating these 
systems as possible formulations to protect against CVDs 
(Giannouli et al. 2018). Work is ongoing to further explore 
the in vitro and in vivo potential of these particles.
Micelles
Micelles are amphiphilic structures with characteristic 
hydrophobic cores and hydrophilic shells, fashioned from 
either polymer- or lipid-based amphiphilic molecules (Gupta 
2011). They form spontaneously due to a reduction in free 
energy arising from aggregation of the hydrophobic por-
tions from the aqueous surrounding, and the creation of a 
micelle core stabilised with hydrophilic fragments exposed 
to the water (Mourya et al. 2011). As the concentration of 
an amphiphile increases in solution, an increase in the free 
energy of the system occurs due to the unfavourable condi-
tions of the environment, as a result of interactions between 
water and the hydrophobic section of the amphiphile, which 
results in a decrease in the system entropy and structuring 
of the water in solution (Letchford and Burt 2007). Micelles 
are formed as the critical micelle concentration (CMC) is 
reached (Trinh et al. 2017). The formation of micelles at the 
CMC lessens the number of undesirable interactions with 
water as the hydrophobic moieties are effectively removed 
from the aqueous environment. The hydrophobic nature of 
the core allows for encapsulation of drugs, and the hydro-
philic shell increases circulation time and systemic exposure 
to the micelle. Their small size and physicochemical prop-
erties allow for entry into tissues by crossing membranes 
(Eniola-Adefeso et al. 2012). Polymeric nanoparticles pos-
sess increased stability compared to low-molecular-weight 
surfactants and liposomes; this is due to their extremely low 
excipient:drug ratios. Hence, there is reduced chance of 
systemic toxicity resulting from the carrier vehicle but also 
makes them more cost-effective. The synthesis is highly con-
trollable, and they can easily be tailor made to application, 
i.e., addition of targeting ligands or tracking molecules. Most 
commonly, the polymers used for micellar drug delivery are 
comprised of polyester or poly(amino acid) derivatives to 
form the hydrophobic region (Gaucher et al. 2005). Forms 
of polyester that are approved for use in human applications 
include poly(lactic acid) (PLA), poly(ɛ-caprolactone) (PCL), 
and poly(glycolic acid) due to their biocompatibility, biodeg-
radability, and structural properties (Gaucher et al. 2005). 
Reports on the use of polymeric micelles for cardiovascular 
disease are rapidly emerging in the literature (Ma et al. 2017; 
Chmielowski et al. 2017; Singla et al. 2018; Wu et al. 2018).
An in vitro study demonstrated successfully the use of a 
block co-polymer micelle formed from poly(ethylene glycol)
(PEG)-block-polycation carrying a (PEG-b-P[Asp(DET)]) 
side chain as a gene delivery vector for treatment of vascular 
disease, with efficient gene expression and low cytotoxic-
ity in vascular smooth muscle cells (Akagi et al. 2007). To 
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fully understand the in vivo outcome of gene transfer, the 
PEG-b-P[Asp(DET)] micellar formulation was implanted 
to a rabbit carotid artery and the degree of gene expres-
sion of plasmid DNA (pDNA) to the vascular region was 
determined. The carotid was wounded using a balloon 
catheter, inducing neointimal hyperplasia, and the encap-
sulated pDNA was administered. The presence of pDNA 
was detected using the FLAG sequence (p-MP-FLAG). The 
artery was stained with an anti-FLAG antibody to confirm 
the expression of the gene, the results of which confirmed 
that the micellar formulation was superior in comparison 
to the controls, homopolymer P[Asp(DET)], and branched 
polyethyleneimine (BPEI). The control vectors displayed a 
significant vessel occlusion by thrombus, which the micel-
lar vectors studied did not exhibit (Akagi et al. 2007). The 
results of this study show that limitations with the current 
technology which uses viral vectors, such as antigenicity 
and oncogenicity, directs research towards use of non-viral 
vectors, since the safety and efficacy profiles of nanomicelles 
are superior (Kagaya et al. 2011).
Recently, an intelligent delivery system which responds to 
the oxidative atherosclerotic plaque microenvironment was 
reported (Wu et al. 2018). Block copolymer micelles were 
constructed using poly(ethylene glycol) and poly(propylene 
sulphide) (PEG-PPS). The micelles were used to solubilise 
andrographolide to decrease inflammatory response and the 
level of reactive oxygen species (ROS) for atherosclerosis 
treatment. Andrographolide is a plant-derived compound 
which exhibits cardiovascular protection effects via down-
regulation of inducible nitric oxide synthase expression and 
upregulation of endothelial nitric oxide synthase expression 
(Kajal et al. 2016). The stimuli responsive micelles formed 
resulted in rapid drug release triggered by the ROS, but also 
consumed the ROS by itself at the pathologic sites, resulting 
in the suppression of the pro-inflammatory cytokines (Wu 
et al. 2018). The authors concluded that the novel formula-
tion demonstrated excellent therapeutic effects both in vitro 
and in vivo, and hence, it may have promising potential 
against atherosclerosis (Wu et al. 2018).
Cationic-mixed polymeric micelles have been developed 
for targeted delivery of lumbrokinase (LK) for the treatment 
of thrombosis (Pan et al. 2018). LK is a fibrinolytic enzyme 
originated from earthworm which has shown to possess 
antithrombotic action (Wang et al. 2013). The micelles con-
sisted of a block copolymer of polycaprolactone-b-poly(2-
(dimethylamino) ethyl methacrylate) (PCL-PDMAEMA), 
as well as a block copolymer of methoxy polyethylene gly-
col-b-polycaprolactone (mPEG-PCL) missed with a block 
copolymer of polycaprolactone-b-polyethylene glycol with 
an RGD peptide conjugated (PCL-PEG-RGDfk) forming a 
treatment known as LKTM (Pan et al. 2018). The formula-
tions were tested in vivo in a thrombosis model in mice. The 
study showed that those mice treated with LKTM exhibited 
a significantly shorter tail bleeding time compared to those 
treated with LK alone or the LK micelles without target-
ing, hence, suggesting that the novel LKTM had effectively 
reduced the bleeding risk (Pan et al. 2018).
Other mixed micelle systems reported include the blend-
ing of different  Pluronic® mixtures (F127 &P123) for the 
solubilisation of olmesartan medoxomil (OLM) (El-Gendy 
et al. 2017). OLM is an antihypertensive drug with poor 
aqueous solubility which results in low bioavailability (Nor-
wood et al. 2002) OLM was loaded into mixed micelles car-
riers to overcome this physicochemical barrier. Three drugs: 
 Pluronic® mixture ratios (1:40, 1:50, and 1:60) and various 
F127:P123 ratios were prepared. The study showed that the 
mixed micelles were capable of up to 43% release efficiency 
compared to 35% in the drug suspension (El-Gendy et al. 
2017).
Dendrimers
The term dendrimer stems from the Greek ‘dendron’, mean-
ing tree, accurately reflecting the structure of these repeat-
edly branched molecules (Crampton and Simanek 2007). 
The uniqueness of dendrimers stems from their multi-
branched, three-dimensional architecture, coupled with low 
polydispersity and great functionality (Sherje et al. 2018). 
There are many apparent advantages to the utilisation of 
dendrimers as non-viral vectors for therapeutic indications, 
as opposed to other nanotechnologies. Their high solubil-
ity, greater stability, minimal immunogenicity, and ability 
to facilitate effective delivery of drug molecules, DNA, and 
RNAs make them superior to other viral and non-viral coun-
terparts (Mendes et al. 2017). One drawback to dendrimers 
is that they often possess highly charged exteriors due to 
their high number of branches at their surface all with their 
own surface charges; this can often result in either highly 
cationic or highly anionic nature and, if not fully addressed, 
can lead to toxicity issues (Jain et al. 2010).
The topology of dendrimers is classified as the focal 
core, multiple peripheral functional groups, and building 
blocks with a number of repeating units within the inner 
core (Jang and Aida 2003). The focal core within a den-
drimer has been exploited to host chemical species within, 
due to the nanoscale environment generated through exten-
sive branching. Second, dendrimers can display various, 
multiple functional groups on the periphery, allowing for 
a variety of interactions between other dendrimers and the 
surrounding molecular environment. Coupled with this, the 
repeated units permit flexibility within the dendrimer, allow-
ing for the manipulation and encapsulation of drug mol-
ecules within (Jang and Aida 2003). The exclusivity of these 
properties to dendritic molecules gives rise to the possibility 
for their use as drug delivery systems. The improved efficacy 
and lower leakage percentages in dendrimers make them 
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more suitable in various formulations, including oral, ocular, 
and transdermal, since the pharmacokinetic parameters for 
dendrimers are also promising (Yu et al. 2015).
Nitric oxide (NO) is a potent vasodilator, regulator of 
vascular cell proliferation, and maintains vascular homeosta-
sis. Due to these effects, it can, therefore, play a key role in 
preventing atherosclerosis (Napoli et al. 2006). Studies have 
shown that there is potential for NO encapsulation within 
dendrimers as a targeted therapy for damaged tissue. Lu 
et al. (2011) reported that NO release was successful from 
poly(propylene imine) dendrimers, which shows promise 
in their potential uses as drug delivery systems (Lu et al. 
2011). Dendrimers with potential as gene delivery agents 
for the treatment of CVDs have also been investigated, in 
an effort to control the upregulation of inflammation in tar-
geted sites within insulted vasculature. Studies have shown 
that dendrimers carrying DNA plasmids enhanced surviv-
ability, stability, and viability of the gene within the nucleus 
(Gothwal et al. 2015), demonstrating viability as prospective 
therapeutic agents.
Recently, a dendrimer composed of poly(glutamic acid) 
and poly(ethylene glycol) (PEG) (Gn-PEG-Gn) was reported 
for the delivery of nattokinase (NK) (Zhang et al. 2017). 
NK is a thrombolytic drug, which possessed high safety 
levels and low side effects, however, extremely sensitive to 
degradation from the external environment. Hence, careful 
formulation is required for the drug to be clinically useful. 
The NK-loaded G3-PEG-G3 dendrimer formed exhibited 
excellent thrombolytic activity in vitro, and further work 
is ongoing to elucidate the in vivo potential of this system 
(Zhang et al. 2017).
Another study reported the development of a 
poly(amidoamine) (PAMAM) dendrimer-based system as 
drug carriers for combined delivery of ramipril (RAPL) and 
hydrochlorothiazide (HCTZ) (Singh et al. 2017). RAPL is an 
antihypertensive drug and HCTZ is a diuretics drug, both of 
which are used in the treatment of high blood pressure (de 
Leeuw and Birkenhäger 1987; Roush and Sica 2016). At 
0.8% (w/v), dendrimer concentration the RAPL solubility 
was increased 4.91-fold with amine-terminated dendrimer, 
whilst the optimal dendrimer for HCTZ solubilisation (3.72-
fold) was with carboxy-terminated functional groups. The 
novel formulations resulted in more rapid dissolution com-
pared to the free drugs. Hybrid formulations showed similar 
dissolution patterns compared to the single drug-loaded den-
drimer. The authors concluded that the formulation strategy 
held promise for application and more work is ongoing to 
push this technology forward (Singh et al. 2017).
Gel nanoparticles
The least common on the polymer-based particles are the 
gelated nanoparticles. These nanoparticles form at with 
increased polymer concentration into hydrogel matrices into 
which drugs can be incorporated. These systems allow for 
a greater retardation of drug release and greater long-term 
stability (Hamidi et al. 2008).
Regeneration of the ischaemic heart through utilisation of 
vascular endothelial growth factor (VEGF)-loaded core/shell 
nanoparticles and their gelation behaviour was monitored 
to assess vascular cell regeneration (Oh et al. 2010). The 
core of the gel nanoparticle was constituted from lecithin 
containing VEGF, with a shell comprising of Pluronic F-127 
(poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene 
oxide) triblock copolymer) (Oh et al. 2010). The tempera-
ture-induced gel was formed when the nanoparticles were 
added to a solution containing propylene glycol mono-
caprylate at body temperature. Gelated and non-gelated nan-
oparticles were added to the in vivo sample and functional 
analysis tests were conducted on the myocardial tissue. The 
results demonstrated that there was a greater improvement 
to heart function (cardiac output and ejection fraction) with 
gelated VEGF-loaded core/shell nanoparticles as compared 
to non-gelated nanoparticulates (Oh et al. 2010).
Nano‑coated stents
Coronary artery bypass graft (CABG) and percutaneous 
transluminal coronary angioplasty (PTCA)/percutaneous 
coronary intervention (PCI) are invasive therapies used 
commonly within clinical practice to relive blockages in 
myocardial vasculature. CABG involves major cardiac sur-
gery, whereas PTCA is a non-surgical procedure, whereby 
an artery is widened using a balloon and, in some instances, 
is held open using a stent (NICE 2008). The stents used are 
composed of thin wire mesh, which is used to retain suf-
ficient blood flow through the previously occluded artery, 
thus preserving its patency (Fig. 4).
The overbearing issue with the use of stents in reperfu-
sion of cardiac tissue leads to a significant risk of resteno-
sis within the vasculature. Restenosis occurs due to over-
distention of the diseased vessel, resulting in endothelial 
disruption, internal elastic laminal fracture, and medical 
dissection (Bennett 2003). A number of processes con-
tribute to in-stent stenosis including elastic recoil, reloca-
tion of axially positioned plaques, and negative remodel-
ling. Neointima formation is the major cause of in-stent 
Fig. 4  Use of a stent to widen an occluded blood vessel
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stenosis, whereby platelets, mitogens, and cytokines 
aggregate. Cell proliferation results and synthesis of the 
extracellular matrix and collagen lead to the creation of 
the neointima (Bennett 2003).
A method that can be employed to reduce the incidence 
of in-stent stenosis is the use of drug-eluting stents (DES), 
which release the incorporated drug to the locality of its 
placement. The stents can be coated in various polymers, 
such as poly(lactic-co-glycolic acid) (PLGA), polyethylene 
glycol (PEG), and polycaprolactone (PCL) (Acharya et al. 
2012). The use of polyhedral oligomeric silsesquioxane 
poly(carbonate-urea) urethane (POSS-PCU) polymer with 
attached anti-CD34 antibodies was studied as a possible 
nanocomposite polymer to coat bare metal stents, in an 
attempt to improve endothelial revascularisation (Tan et al. 
2013). The results of this study indicated that POSS-PCU 
had advanced biocompatibility and haemo-compatibility 
in vitro. This is further supported by research into the use 
of POSS-PCU in the field of heart valve replacements. Syn-
thetic valves made of POSS-PCU nanocomposites have been 
successfully tested, demonstrating their biocompatibility and 
biostability against oxidation, hydrolysis, and enzymatic 
attack in vitro and in vivo (Kidane et al. 2009). However, 
it has also been demonstrated that the use of drug-eluting 
stents in animal models led to delayed arterial healing and 
promoted inflammation at the site of the overlap in the 
implanted stents. Overlapping paclitaxel-eluting stents (PES) 
showed a greater degree of fibrin deposition and neointima 
formation, raising concerns over safety in human subjects, 
drug toxicity, and further systemic complications arising 
from sites of overlap (Finn et al. 2005). Use of POSS-PCU 
as a nanocomposite coating on stents has been taken for-
ward into human trials. The first-in-man trial (FIM) studied 
the efficacy and long-term implications of non-polymeric 
drug-coated stents (DCS) in patients with de novo coronary 
artery disease, with follow-up times of 4 months, 12 months, 
and 5 years. Notably, at 4 months, there was a significantly 
lower rate of lumen loss with the DCS than PES. The results 
demonstrated no inferiority to PES in the rate of lumen loss, 
a subclass of neointimal hyperplasia (Costa et al. 2016). The 
use of nano-coatings on stents is being trialled currently in 
the United States: The COBRA PzF Stenting to Reduce 
the Duration of Triple Therapy in Patients Treated With 
Oral Anticoagulation Undergoing Percutaneous Coronary 
Intervention trial is ongoing and aims to investigate if the 
COBRA PzF stent with a polyzene-F nano-coating can suc-
cessfully reduce bleeding compared to DES, through reduc-
ing the duration of oral anticoagulation therapy to 14 days, 
rather than the current 6 months, in patients undergoing PCI 
(US National Library of Medicine 2018). Polyzene-F is a 
new generation nano-coating based on cobalt–chromium, 
designed to be highly biocompatible and easily deliverable 
(CeloNova Biosciences 2018).
Stents and drug-eluting stents are one of the most estab-
lished technologies for cardiovascular disease treatment. 
However, as discussed, there are problems in their usage, 
and although nanotechnology has been employed in their 
coating to reduce occurrence of rejection in vivo and reste-
nosis, there is a move away from these technology towards 
flexible polymer scaffolds.
Nanoparticles for diagnostic imaging
Nanoparticles also have a place in medicine to fulfil an 
unmet need in the field of imaging. Nanoparticles offer real 
potential in medical imaging due to their good bioavail-
ability profiles, versatility of use, and ease of manipulation. 
Nanoparticles offer adaptable qualities to generate multi-
modal and multifunctional imaging vehicles with modifi-
able features, allowing for the integration of contrast mate-
rials, ligands, and functional groups (Stendahl and Sinusas 
2015). Cardiovascular magnetic resonance (CMR) is a non-
invasive method for the detection of inflammation: Due to 
the pathophysiology of coronary heart disease, inflamma-
tion is a major complication of the illness, and early detec-
tion through the utilisation of these methods can improve 
prognosis. CMR relies on the observation of changes in 
myocardial tissue configuration (Bietenbeck et al. 2015). 
Gadolinium shows the composition of plaques, including 
the details of the fibrous cap, necrotic core (Cai et al. 2005), 
macrophage content, and extent of plaque revascularisation 
(Kampschulte et al. 2004). Furthermore, contrast-enhanced 
CMR (ceCMR) can be employed for the recognition of 
myocardial oedema, necrosis, and fibrosis, using gado-
linium or fluorine-19 (19F) contrast agents (Friedrich et al. 
2009). Healthy myocardium clears the contrast agent rap-
idly, while damaged tissues retain the dye (Bietenbeck et al. 
2015). T1-weighted imaging established CMR imaging as a 
technique, whereby gadolinium-contrast agent was detected 
in > 90% of the myocardium following insult as a result of 
induced MI in in vivo models, successfully demonstrating 
the accuracy of CMR as a diagnostic tool (Kim et al. 1996). 
Such advances in diagnostic imaging will also allow a better 
patient-centred therapy, by clearer identification of athero-
sclerotic plaques and the extent of atherosclerosis to guide 
the dosage of statins required to have a better prophylactic 
effect, for example.
Gold nanoparticles have also shown great promise in both 
cardiovascular medicine and oncology imaging. Gold is a 
noble metal and essentially an inert material which is stable 
and biocompatible (Thakor et al. 2011). Gold particulates 
occur in a variety of shapes and sizes, including rods, spheres, 
cages, stars, crescents, and prisms, with sizes varying from 
1 to 500 nm. Gold particles are excreted renally. The elimi-
nation rate through glomerular filtration can be modified by 
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attaching PEG chains to the nanoparticle surface to increase 
hydrophilicity and circulation time of the nanoparticle (Varna 
et al. 2018). Gold nanoparticles can be used in cardiovascular 
optical imaging: photoacoustic imaging is based on detection 
of both ultrasound and optical imaging, whereby light is used 
a source of excitation and ultrasound detects sound waves gen-
erated by the target, generating images of optical absorption 
(Chen et al. 2014).
Future perspectives
Medical technology and treatments for CVDs, in particular, 
have significantly advanced in an aim to increase the quality 
of and prolong life. It is imperative to find better solutions 
for the treatment of CVD as it is estimated that only 15% of 
current guidelines for practice are supported by high-quality 
evidence (Califf 2016). Better lifestyle, diet, medial interven-
tion, earlier detection, prevention strategies, and improved 
standard of living have all contributed to better prognoses. 
A large proportion of all premature deaths under the age 
of 75, within persons whom are residents of the European 
Union are due to CVDs. Therefore, it is imperative that solu-
tions are sought quickly to effectively treat this pandemic, 
with the goal to prevent around 80% of all cardiovascular 
diseases through the use of nanotechnologies (Letourneur 
et al. 2014). As of 2014, a study showed that there were 
122 nanomedicines going through clinical development, of 
which 17 had made it to phase II or III trials (Letourneur 
et al. 2014). Of those in progress, 70 products were oncol-
ogy based, 19 for infectious diseases, and only 7 for cardio-
vascular medicine (Letourneur et al. 2014). This highlights 
the desperate need for greater research and development in 
this field. There are a number of current, ongoing trials into 
the therapeutic use of nanotechnology in cardiovascular 
medicine, notably, the NanoAthero project, funded by the 
European Commission. The objectives of this phase I trial 
include successfully undertaking thrombus imaging and 
treating vulnerable plaques using novel carriers (European 
Commission 2017). Further to this, Habib et al. are cur-
rently studying the possibility of diagnosing heart failure 
using breath samples and sensors based on nanomaterials 
(US National Library of Medicine 2018). Further clinical 
trials are being conducted in the uses of nanotechnology 
in drug-eluting stents in comparison to bare metal stents: 
The research has a participant size of 8000 and thus far has 
demonstrated the promising results (US National Library of 
Medicine 2018).
Conclusion
The evidence presented within this review demonstrates 
that nanotechnology does hold potential for application 
in the treatment of CVD, demonstrated by translational 
clinical trials. With increasing investment into the field of 
nanotechnology and suitable infrastructure worldwide, it is 
only a matter of time before nanomedicines, nanomaterial 
devices, and other related technologies successfully com-
plete the rigorous clinical trial process and come onto the 
market. A certainty is that nanotechnology holds promise to 
improve patient health and well-being, and that any progres-
sion on the current therapies will positively impact the lives 
of patients globally. To have the greatest possible impact in 
medicine, more in vivo studies will need to be conducted 
and clinical trials commissioned to fully understand the 
behaviours of nanoparticulates systemically. As the future in 
therapeutics is becoming more geared towards personalised 
medicine, nanotechnology may be best placed to achieve 
this intended goal to tailor treatment to individual disease 
states. Furthermore, increasing healthcare costs mean that it 
is imperative to seek alternatives to the existing pharmaco-
logical and surgical management, to curb these exponential 
increases. However, there is substantial evidence to sup-
port the concept that nanotechnology is yet to make its full 
impact to revolutionise medicine.
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